Multiple major histocompatibility complex (MHC) loci encoding human leukocyte antigens (HLA) have allelic variants unequivocally associated with differential immune control of HIV-1 infection. Fine mapping based on single nucleotide polymorphisms (SNPs) in the extended MHC (xMHC) region is expected to reveal causal or novel factors and to justify a search for functional mechanisms. We have tested the utility of a custom fine-mapping platform (the ImmunoChip) for 172 HIV-1 seroconverters (SCs) and 449 seroprevalent individuals (SPs) from Lusaka, Zambia, with a focus on more than 6400 informative xMHC SNPs. When conditioned on HLA and nongenetic factors previously associated with HIV-1 viral load (VL) in the study cohort, penalized approaches (HyperLasso models) identified an intergenic SNP (rs3094626 between RPP21 and HLA-E) and an intronic SNP (rs3134931 in NOTCH4) as novel correlates of early set-point VL in SCs. The minor allele of rs2857114 (downstream from HLA-DOB) was an unfavorable factor in SPs. Joint models based on demographic features, HLA alleles and the newly identified SNP variants could explain 29% and 15% of VL variance in SCs and SPs, respectively. These findings and bioinformatics strongly suggest that both classic and nonclassic MHC genes deserve further investigation, especially in Africans with relatively short haplotype blocks.
INTRODUCTION
In the era of genome-wide association studies (GWAS), the search for definitive host genetic factors underlying effective immune control of HIV-1 infection is yet to yield convincing results beyond those already obtained through hypothesis-driven approaches. 1 To date, the most consistent observations center on the importance of human leukocyte antigen class I (HLA-I) genes within the human major histocompatibility complex (MHC) region on chromosome 6p21, although other candidates in the extended MHC (xMHC) may also play some role. 2, 3 From the nine HIV-1related GWAS, [4] [5] [6] [7] [8] [9] [10] [11] [12] only two single nucleotide polymorphisms (SNPs) within the xMHC have consistently shown favorable impact on set-point viral load (VL): rs2395029 within the HCP5 gene and rs9264942 located 35 kb upstream of HLA-C. Follow-up studies have noted strong linkage disequilibrium (LD) between rs2395029 and HLA-B*57:01, an established allele for favorable outcomes after HIV-1 infection. 10, 13, 14 The majority of reported GWAS have been performed in populations of European ancestry, whereas two have scanned African-American populations, without detecting any robust novel associations with disease progression. 10, 11 The overall lack of consensus in various findings may reflect the evolving viral diversity, as well as the complexity of human population heterogeneity in genetic architecture. 15, 16 Fine mapping of implicated genetic regions in diverse racial groups is an important step in follow-up studies, as variable LD patterns can help resolve specific haplotype blocks for in-depth interrogation of causal variants or primary association signals that are not fully captured by genome-wide scans. 17 In sub-Saharan African populations with the greatest burden of HIV/AIDS and profound genetic diversity, fine mapping of genetic factors related to immune control of HIV-1 infection may help steer future translational research, especially if dense coverage of candidate loci can effectively rule out the uncertainty with local and extended haplotypes.
Previous studies based on a large Zambian cohort with longitudinal data have identified several host genetic factors that have a cumulative impact on VL. [18] [19] [20] [21] [22] These studies have also highlighted the importance of viral evolution and adaptation. [21] [22] [23] [24] With a focus on both early VL in recent HIV-1 seroconverters (SCs) and chronic VL in seroprevalent individuals (SPs), we have tested the utility of a custom genotyping platform (the ImmunoChip) for fine mapping of host genetic factors in the xMHC region.
RESULTS

Characteristics of seroconverted and seroprevalent individuals included for final analysis
A total of 172 eligible SCs and 449 SPs had successful HLA and ImmunoChip genotyping results that met all inclusion criteria and passed several layers of quality control procedures. In comparison of overall characteristics of individuals within the two subgroups (Table 1) , there were more women in the SC group than in the SP group, with a male-to-female sex ratio of 0.6 and 1.1, respectively. On average, SCs were younger than SPs. Previously established HLA factors had similar distribution in SCs and SPs, except that HLA-B*57 (a favorable factor) was more common in SPs (12.9%) than in SCs (7.6%). Mean log 10 -transformed VL was slightly lower in SCs (4.6±0.7) than in SPs (4.8±0.7).
Haplotype blocks defined by informative xMHC SNPs
Following the removal of 591 xMHC SNPs (B7% of the total) known to be duplicates on the ImmunoChip ( Supplementary  Table S1 ), 6417 SNPs in SCs and 6708 in SPs passed several genotyping quality control procedures and showed minor allele frequencies over the analysis thresholds (X0.025 in SCs and X0.015 in SPs, for a minimum of 10 observations in each group) ( Supplementary Tables S2 and S3 ). These informative SNPs divided the xMHC region into 410 haplotype blocks of various sizes ( Supplementary Tables S2 and S3 ), but they rarely tagged HLA class I or class II alleles (that is, pairwise r 2 40.80). Accordingly, major HLA factors pertinent to the study population ( Figures 1 and 2) were mostly independent of the SNP genotypes.
xMHC SNP variants and set-point VL in SCs
Conventional approach to association analyses did not identify any xMHC SNP with an adjusted P-value o2.8 Â 10 À 5 , the threshold for xMHC-wide statistical significance after correction for 1800 independent tests. Several trends (Po0.001) were noted for multiple SNPs mapped to NOTCH4 and to an intergenic region between RPP21 and HLA-E ( Supplementary Table S4 ). On the other hand, high-dimensional HyperLasso model (penalized regression) indicated that three SNPs in the MHC class I region and two others in class II and class III might contribute to VL variability in SCs ( Figure 3a ). These five SNPs, along with sex and age, explained 34.4% of the overall VL variance (Po0.0001) ( Table 2 ). When conditioned further on three prominent HLA factors (A*74, B*13 and B*57), only rs3094626 in the MHC class I region (intergenic between RPP21 and HLA-E) and rs3134931 in class III (intronic within NOTCH4) showed independent contributions to VL variability ( Figure 3b ). In the reduced multivariable model (Table 2) , sex, age, rs3094626 (allele C), rs3134931 (allele G) and the three known HLA factors collectively explained 28.9% of the overall VL variance (Po0.0001). The two MHC SNPs were also among the top hits in single-variant models, with the 11th and 16th ranked P-values, respectively, after statistical adjustment for demographic features and HLA factors ( Supplementary  Table S4 ).
xMHC SNP variants and chronic VL in SPs
When tested individually, no single SNPs reached the Bonferronicorrected, statistical significance threshold for potential association with chronic VL in SPs ( Supplementary Table S5 ). HyperLasso model initially identified two SNPs in the MHC class I region (rs3823376 and rs2517425) and another in class II (rs2875114) as apparent contributors to VL variability in SPs ( Figure 4a ). These three SNPs, along with sex and age, could explain 14.8% of the overall VL variance (Po0.0001) ( Table 3) . Indeed, the allele C for rs2857114, a SNP downstream from HLA-DOB in the MHC class II region, remained as an independent marker associated with an unfavorable VL outcome after additional adjustment for previously identified HLA alleles ( Figure 4b and Table 3 ). The final model explained 14.9% of the overall VL variance (Po0.0001) ( Table 3) .
Findings from bioinformatics
A search in the HaploReg database (http://www.broadinstitute. org/mammals/haploreg/haploreg.php) revealed that the three independent associations (rs3094626, rs3134931 and rs2857114) identified by HyperLasso models were not complicated by tagging SNPs (r 2 X0.80) reported in African populations (Supplementary Figure S1 ). First, neither rs3094626 nor rs3134931 can tag other SNPs. Second, the only SNP (rs2621331 in HLA-DOB) tagged by rs2857114 (r 2 ¼ 1.0) has less functional attributes than rs2857114.
In terms of previously reported associations captured by the NCBI Global Cross-database, rs2857114 has been implicated as an expression QTL for TAP2 and HLA-DOB in B cells and monocytes. 25 In populations of European ancestry, however, two of the three SNPs of major interest have quite different LD patterns (Supplementary Figure S2 ). In particular, rs2857114 can effectively tag 70 other SNPs at the HLA-DOB locus, including two (rs2187684 and rs2257789) that may govern promoter functions; one of these (rs2187684) has been associated with juvenile idiopathic arthritis. 26 No other clues can point to the causal variants.
DISCUSSION
Guided by strong epidemiologic evidence from hypothesis-driven approaches, 21, 22 our study here revealed several xMHC SNPs as novel correlates of differential immune control of HIV-1 infection in an African cohort. Of note, when results obtained from three analytical approaches (linear regression, penalized regression and ordinal regression) are compared side by side for seroconverters (recent HIV-1 infection) and seroprevalent subjects (unknown but longer duration of infection), there is a striking contrast for the list of independent markers at the gene and SNP levels (for example, Figure 3 versus Figure 4 ). In light of the various pathways for viral adaptation and immune escape mutations in individuals and populations, 24, 27, 28 it is now evident that seroconverters and seroprevalent subjects should be treated as distinct subgroups for certain epidemiologic analysis even when they are derived from the same location, because lumping them together (for the sake of statistical power) can obscure the search for early correlates and mechanisms of durable immune control. 21, 29 Our work has also demonstrated that penalized regression can be advantageous when a large number of individual SNPs with modest effects are analyzed. Penalized regression, like HyperLasso, focuses on prediction and not on hypothesis testing, which requires moving away from the usual and overwhelming reliance on P-values in genetic studies. 30 Although the models can be calibrated to offer some control over false discovery rates, regularization also induces biased coefficient estimates and complicates the calculations of s.e. for variables selected into the model. Methods such as HyperLasso typically include the best SNPs out of a pool of closely related variants for characterizing the association. 31 Thus, the resulting models are not necessarily unique, that is, multiple competing models may provide virtually identical predictive accuracy. To this end, it is often necessary to emphasize the specific genes or haplotype blocks rather than the individual SNPs. Surveys based on various databases, including the 1000 Genomes Project, 32 ENCODE 33, 34 and the NCBI Global Crossdatabase, can help narrow the search for consensus findings or causal variants, especially when functional attributes in various cell lineages are known. 25 The novel MHC SNPs identified by two series of HyperLasso models can explain a good proportion of the variability in both Figure 1 , the density of SNP coverage along the MHC region is also shown. Figure 1 , the density of SNP coverage along the MHC region is also shown.
early and chronic VL (Tables 2 and 3) , clearly beyond those already attributed to classical HLA alleles in the Zambian cohort. 22 In particular, the association of allele G for rs3134931 (NOTCH4) with set-point VL has some consistency with reported literature, as two previous studies on HIV-1 have highlighted a nonsynonymous SNP (rs8192591) within exon 9 of NOTCH4, corresponding to Gly534Ser. 8, 35 Similar to our findings on rs3134931-G and high set-point VL, an unfavorable relationship has been reported for rs8192591 and disease progression. 35 The conservative amino acid substitution introduced by rs8192591 is not expected to alter the protein function. 8 The low minor allele frequency for rs8192591 in our study cohort also rules out the possibility of a major impact. In contrast, the allelic variants of rs3134931 (a SNP mapped to an enhancer region) can have distinct binding affinity for PU1 in fibroblasts and T H 1 cells (Supplementary Figure S1) . Although rs3134931-G may well be a causal variant of immunological importance, recognition of NOTCH4 (http://www.ncbi.nlm.nih.gov/ gene/4855) as a hot spot for autoimmune disorders and infectious diseases 8, [35] [36] [37] [38] still justifies an in-depth evaluation of neighboring variants in follow-up studies. The biological relevance of other xMHC SNPs associated with set-point and chronic VL is less obvious, even when LD patterns and other datasets are considered (Supplementary Figure S1) . The association signal for rs2857114 may point to the potential role of HLA-DOB (http://www.ncbi.nlm.nih.gov/gene/3112), a nonclassic HLA gene encoding the DOb chain that forms a heterodimer with HLA-DOa. The DOab complex is typically stored in lysosomes to regulate HLA-DM-mediated loading of antigenic peptides to MHC class II molecules. [39] [40] [41] In the absence of strong LD with known SNPs beyond the HLA-DOB locus, further analysis of rs2857114 in African populations can be highly advantageous because there is little complication by neighboring variants (Supplementary Figure S1) . Conversely, presence of conserved extended haplotypes in populations of European ancestry 42 can obscure the search for causal variants within cis-and trans-acting elements. 25 Several studies have noted the benefits of the popular ImmunoChip for detecting independent association signals for coding variants at many loci. 43, 44 By design, the ImmunoChip may allow for fine mapping in populations of European ancestry, with clear improvement for SNP coverage when compared with existing GWAS arrays. 45, 46 However, as far as the xMHC region is concerned, the first-generation ImmunoChip still has a major caveat in its lack of dense coverage (for example, Figure 1) , especially for coding SNPs (Supplementary Tables S2 and S3 ). It is also apparent that multiple MHC SNPs (that is, rs2395029 and rs9264942) highly relevant to HIV/AIDS and other infectious diseases are not covered at all by the ImmunoChip. Our statistical models should continue to improve when fine mapping based on sequencing can adequately capture variants in both classic and nonclassic MHC loci. Further analyses of rare variants in large cohort should be informative as well. Future generations of the ImmunoChip may need to meet these needs and minimize uncertainties about coverage for the xMHC region.
PATIENTS AND METHODS
Study population
Subjects available for this study came from the Zambia-Emory HIV-1 Research Project. On the basis of HIV-1 infection status at the time of enrollment, subjects were classified into two subgroups: 242 seroconverters (SCs) who became infected during quarterly follow-up visits and 482 SPs who were already infected at baseline. The overall study design and followup strategies have been described in detail elsewhere for this cohort. [47] [48] [49] 
Ethical aspects
The research outlined in this study was approved by the institutional review boards at clinical sites in Lusaka, Zambia, and at two collaborating institutions (Emory University and University of Alabama at Birmingham) in the US. All subjects gave written informed consent for screening and participation.
Assessment of virologic outcomes
Plasma VL was measured as HIV-1 RNA concentration (copies ml À 1 ) using the Roche Amplicor 1.0 assay (Roche Diagnostics Systems Inc., Branchburg, NJ, USA) in a laboratory certified by the virology quality assurance program of the AIDS Clinical Trial Group. Results after the initiation of antiretroviral therapy were censored. For SCs, set-point VL corresponded to the log 10transformed geometric mean of all available VL measurements during the 3-12 months interval after the estimated date of infection. For SPs, the first log 10 -transformed VL measurement available was used for analysis. Subjects (49 SCs and 5 SPs) who had missing VL data were excluded first, so were those (5 SCs and 13 SPs) who had VL below the lower limit of detection (that is, o400 copies ml À 1 ). The remaining SCs (n ¼ 188) and SPs (n ¼ 464) were retained for further analyses.
Genotyping
Allelic variants for three classic HLA class I genes (HLA-A, HLA-B and HLA-C) and two HLA class II loci (HLA-DRB1 and HLA-DQB1) were resolved to the first four digits (distinct protein sequences) using a combination of PCRbased methods, including PCR with sequence-specific primers (Dynal/ Invitrogen, Brown Deer, WI, USA), automated sequence-specific oligonucleotide probe hybridization (Innogenetics, Alpharetta, GA, USA) and sequencing-based typing (Abbott Molecular, Inc., Des Plaines, IL, USA). SNP genotyping with the Illumina ImmunoChip 46 was processed at a genomics core facility (University of Alabama at Birmingham); SNP alleles were inferred using the joint calling and haplotype phasing algorithm implemented in BEAGLECALL. 50 We completed a series of data cleaning and quality control procedures for SNPs in the xMHC region, excluding SNPs based on the following criteria: (i) duplication ( Supplementary  Table S1 ), (ii) missingness (call rateo98.5%), (iii) minor allele frequency o0.025 in SCs and o0.015 in SPs and (iv) deviation from Hardy-Weinberg Table S3 ) and 6708 SNPs in SPs ( Supplementary  Table S3 ) were mapped to the xMHC region (B7.5 Mb between rs498548 and rs2772390). 51 Data cleaning based on ImmunoChip results and population stratification Subjects with ImmunoChip data were further evaluated against three additional (and occasionally overlapping) quality control criteria for final exclusion: (i) overall call rates o95% (8 SCs and 3 SPs), (ii) failing sex determination (n ¼ 0) and (iii) up to third degree familial relationships (4 SCs and 5 SPs) according to kinship coefficients (the KING software package). 52, 53 Population stratification was assessed using multidimensional scaling implemented in KING. 53, 54 We gathered SNP data for 1184 unrelated individuals from the 11 study populations in phase 3 of the International HapMap Project, defined by the Illumina 1M and Affymetrix 6.0 genome-wide SNP arrays (Affymetrix, Santa Clara, CA, USA). For the multidimensional scaling analysis, we used a subset of SNPs (B30 000) that were (i) annotated with reference sequence (rs) IDs on the ImmunoChip, (ii) outside of regions of known extended LD in European populations and (iii) reliably aligned with the HapMap 3 data (that is, removing SNPs with ambiguous A/T and C/G variants). 55 The multidimensional scaling data revealed four outliers (1 SC and 3 SPs, possibly immigrants) that were not suitable for final analysis.
Analysis of general features and population genetics
The overall characteristics of SCs and SPs were compared using Student's t-test (for continuous variables), w 2 test (for categorical variables) and the Wilcoxon-Mann-Whitney test (for nonparametric variables) ( Table 1) . HLA alleles and xMHC SNP genotypes in SCs and SPs were also analyzed separately for patterns of LD, with SNPs assigned to individual haplotype blocks using HaploView 56 whenever possible ( Supplementary Tables S2  and S3 ). SNPs that can effectively tag individual HLA alleles (pairwise r 2 40.80) received special attention, especially in terms of their physical location (relative to the HLA alleles and other MHC genes) and potential function (transcription and translation).
Strategies for association analysis
To effectively identify novel SNPs that are independently associated with VL outcomes in SCs and SPs, we adopted a high-dimension method known as penalized regression (HyperLasso), 31 which tests all eligible xMHC SNPs at once and minimizes the risk of false discovery from random testing. The HyperLasso model uses a hierarchical normal-exponential-gamma regression coefficient, which is parameterized in terms of shape and scale. On the basis of the method reported by Vignal et al., 57 the shape parameter was set to 1, and 100 null permutations were analyzed for both the SC and SP datasets (for a given set of non-SNP covariates, that is, nongenetic factors and previously identified HLA alleles) over a grid of scale parameter values. The null datasets were created by randomly pairing phenotypes/nongenetic covariates with genotypes (thus maintaining the relationship between the nongenetic covariates and VLs). We then selected a value for the scale parameter that allowed not more than one spurious SNP signal in the final regression model. The minor alleles of individual SNPs were tested for additive effect, and they were included only if the minor allele was observed in at least 10 subjects (either heterozygote or homozygote) in a given dataset. For analyses of set-point VL in SCs, the HyperLasso model was adjusted for potential effects of sex, age at estimated date of infection and three known HLA factors (A*74, B*13 and B*57). 21 Analyses of chronic VL in SPs were conditioned on sex, age at VL measurement and five known HLA factors (HLA-A*36, A*74, B*57, B*81 and DRB1*01:02) as reported earlier. 21 To facilitate comparison with findings from multiple GWAS, we also applied a standard approach to testing individual candidate SNPs and ranked them based on their adjusted P-values in generalized linear models (SAS version 9.2, Cary, NC, USA). To account for the widespread LD within the xMHC region, SimpleM (available at https://dsgweb.wustl.edu/rgao/) was used to calculate the number of independent tests for Bonferroni correction of P-values. 58, 59 For both SCs and SPs, the SimpleM estimate for the number of independent tests was nearly 1800. Thus, a P-value of 2.8 Â 10 À 5 was considered statistically significant for the MHC-wide random testing for individual SNPs.
For all linear regression models, the assumption of a normal VL data distribution was assessed using the Kolmogorov-Smirnov test. The standard log 10 -transformation of VL helped with data normalization, but Box-Cox transformation of log 10 VL was generally applicable to separate analyses of SCs and SPs. We further obtained summary statistics (proportion odds ratios, 95% confidence intervals and P-values) from ordinal logistic regression models for three VL categories: (i) o10 000 copies ml À 1 (low), (ii) 10 000-100 000 copies ml À 1 (medium) and (iii) 4100 000 copies ml À 1 (high). This alternative strategy is expected to alleviate concerns about minor VL fluctuations within individuals and inter-assay variability in VL data. More importantly, these VL categories have strong and persistent implications for rates of heterosexual HIV-1 transmission. 47, 60 Bioinformatics for individual SNPs of interest To gather evidence for functional relevance, SNPs associated with HIV-1 VL in HyperLasso models were first queried in HaploReg 61 for known LD with SNPs documented by the 1000 Genomes Project (not necessarily covered by the ImmunoChip) or annotated by the ENCODE project. 33, 34 MHC SNPs implicated for other diseases (dbGaP) and/or gene expression QTL (eQTL) in various cell lines 25 were also surveyed (NCBI Global Cross-database, http:// www.ncbi.nlm.nih.gov/), with a focus on functional attributes in cells that mediate immune pathways. These procedures further took into account (i) cis-and trans-acting elements, (ii) local haplotypes resolved by HaploView 56 and (iii) conserved extended haplotypes known for various HLA alleles. 42 
